I had an hour phone conversation with Scynexis (SCYX) CEO Marco Taglietti last week. Key takeaways are summarized below.
Data so far shows that Scynexis clearly has a novel antifungal asset, which can be used in both outpatient and hospitalized patient settings. The oral form of Ibrexafungerp (Ibra) showed good efficacy against refractory invasive candida infections, so the concern that there is no IV form is alleviated. Oral form achieved good blood and tissue levels in hospitalized patients.
Recent Candida Auris data has provided the company visibility in the scientific community and the